Medicinal cannabis for Alzheimer's disease

Genevieve Z. Steiner-Lim; Madilyn Coles; Kayla Jaye; Najwa-Joelle Metri; Ali S. Butt; Katerina Christofides; Jackson McPartland; Zainab Al-Modhefer; Diana Karamacoska; Ethan Russo; Tim Karl

doi:10.4018/978-1-6684-5652-1.ch001

Medicinal cannabis for Alzheimer's disease

Genevieve Z. Steiner-Lim, Madilyn Coles, Kayla Jaye, Najwa-Joelle Metri, Ali S. Butt, Katerina Christofides, Jackson McPartland, Zainab Al-Modhefer, Diana Karamacoska, Ethan Russo, Tim Karl

Research output: Chapter in Book / Conference Paper › Chapter

1 Citation (Scopus)

Abstract

Alzheimer's disease (AD) is the most common form of dementia, and currently there is no cure. New therapeutic strategies that have the potential to address the complex pathophysiology of AD are urgently required; medicinal cannabis offers this possibility. Several potential leads can be extractedfrom Cannabis sativa ( cannabis) that can target AD pathophysiology and alleviate symptoms, making it a prime candidate for AD drug discovery research. To date, most cannabis and AD research has focused on the major cannabinoids A9-tetrahydrocannabinol (THC) and cannabidiol (CBD), paying little attention to other plant constituents with therapeutic properties for AD. This chapter will highlight emerging evidence on the therapeutic potential of medicinal cannabis going beyond CBD and THC to discuss cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabinoid acids, and other cannabinoid homologs, terpenes, and flavonoids that may have relevance to AD therapy. Further, the entourage effect, clinical implications, and directions for future research will be discussed.

Original language	English
Title of host publication	Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson’s, and Other Neurodegenerative Diseases
Editors	Rana R. Zeine, Brian W. Teasdale
Place of Publication	U.S.
Publisher	IGI Global
Pages	1-47
Number of pages	47
ISBN (Electronic)	9781668456538
ISBN (Print)	9781668456521
DOIs	https://doi.org/10.4018/978-1-6684-5652-1.ch001
Publication status	Published - 7 Mar 2023

Bibliographical note

Publisher Copyright:
© 2023, IGI Global.

Access to Document

10.4018/978-1-6684-5652-1.ch001

Cite this

Steiner-Lim, G. Z., Coles, M., Jaye, K., Metri, N.-J., Butt, A. S., Christofides, K., McPartland, J., Al-Modhefer, Z., Karamacoska, D., Russo, E., & Karl, T. (2023). Medicinal cannabis for Alzheimer's disease. In R. R. Zeine, & B. W. Teasdale (Eds.), Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson’s, and Other Neurodegenerative Diseases (pp. 1-47). IGI Global. https://doi.org/10.4018/978-1-6684-5652-1.ch001

@inbook{0a3056ec739749bc8021616efd15c0d3,

title = "Medicinal cannabis for Alzheimer's disease",

abstract = "Alzheimer's disease (AD) is the most common form of dementia, and currently there is no cure. New therapeutic strategies that have the potential to address the complex pathophysiology of AD are urgently required; medicinal cannabis offers this possibility. Several potential leads can be extractedfrom Cannabis sativa ( cannabis) that can target AD pathophysiology and alleviate symptoms, making it a prime candidate for AD drug discovery research. To date, most cannabis and AD research has focused on the major cannabinoids A9-tetrahydrocannabinol (THC) and cannabidiol (CBD), paying little attention to other plant constituents with therapeutic properties for AD. This chapter will highlight emerging evidence on the therapeutic potential of medicinal cannabis going beyond CBD and THC to discuss cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabinoid acids, and other cannabinoid homologs, terpenes, and flavonoids that may have relevance to AD therapy. Further, the entourage effect, clinical implications, and directions for future research will be discussed.",

author = "Steiner-Lim, {Genevieve Z.} and Madilyn Coles and Kayla Jaye and Najwa-Joelle Metri and Butt, {Ali S.} and Katerina Christofides and Jackson McPartland and Zainab Al-Modhefer and Diana Karamacoska and Ethan Russo and Tim Karl",

note = "Publisher Copyright: {\textcopyright} 2023, IGI Global.",

year = "2023",

month = mar,

day = "7",

doi = "10.4018/978-1-6684-5652-1.ch001",

language = "English",

isbn = "9781668456521",

pages = "1--47",

editor = "Zeine, {Rana R.} and Teasdale, {Brian W.}",

booktitle = "Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson{\textquoteright}s, and Other Neurodegenerative Diseases",

publisher = "IGI Global",

}

Steiner-Lim, GZ , Coles, M, Jaye, K, Metri, N-J, Butt, AS, Christofides, K, McPartland, J, Al-Modhefer, Z, Karamacoska, D, Russo, E & Karl, T 2023, Medicinal cannabis for Alzheimer's disease. in RR Zeine & BW Teasdale (eds), Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson’s, and Other Neurodegenerative Diseases. IGI Global, U.S., pp. 1-47. https://doi.org/10.4018/978-1-6684-5652-1.ch001

Medicinal cannabis for Alzheimer's disease. / Steiner-Lim, Genevieve Z.; Coles, Madilyn; Jaye, Kayla et al.
Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson’s, and Other Neurodegenerative Diseases. ed. / Rana R. Zeine; Brian W. Teasdale. U.S.: IGI Global, 2023. p. 1-47.

Research output: Chapter in Book / Conference Paper › Chapter

TY - CHAP

T1 - Medicinal cannabis for Alzheimer's disease

AU - Steiner-Lim, Genevieve Z.

AU - Coles, Madilyn

AU - Jaye, Kayla

AU - Metri, Najwa-Joelle

AU - Butt, Ali S.

AU - Christofides, Katerina

AU - McPartland, Jackson

AU - Al-Modhefer, Zainab

AU - Karamacoska, Diana

AU - Russo, Ethan

AU - Karl, Tim

PY - 2023/3/7

Y1 - 2023/3/7

N2 - Alzheimer's disease (AD) is the most common form of dementia, and currently there is no cure. New therapeutic strategies that have the potential to address the complex pathophysiology of AD are urgently required; medicinal cannabis offers this possibility. Several potential leads can be extractedfrom Cannabis sativa ( cannabis) that can target AD pathophysiology and alleviate symptoms, making it a prime candidate for AD drug discovery research. To date, most cannabis and AD research has focused on the major cannabinoids A9-tetrahydrocannabinol (THC) and cannabidiol (CBD), paying little attention to other plant constituents with therapeutic properties for AD. This chapter will highlight emerging evidence on the therapeutic potential of medicinal cannabis going beyond CBD and THC to discuss cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabinoid acids, and other cannabinoid homologs, terpenes, and flavonoids that may have relevance to AD therapy. Further, the entourage effect, clinical implications, and directions for future research will be discussed.

AB - Alzheimer's disease (AD) is the most common form of dementia, and currently there is no cure. New therapeutic strategies that have the potential to address the complex pathophysiology of AD are urgently required; medicinal cannabis offers this possibility. Several potential leads can be extractedfrom Cannabis sativa ( cannabis) that can target AD pathophysiology and alleviate symptoms, making it a prime candidate for AD drug discovery research. To date, most cannabis and AD research has focused on the major cannabinoids A9-tetrahydrocannabinol (THC) and cannabidiol (CBD), paying little attention to other plant constituents with therapeutic properties for AD. This chapter will highlight emerging evidence on the therapeutic potential of medicinal cannabis going beyond CBD and THC to discuss cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabinoid acids, and other cannabinoid homologs, terpenes, and flavonoids that may have relevance to AD therapy. Further, the entourage effect, clinical implications, and directions for future research will be discussed.

UR - https://hdl.handle.net/1959.7/uws:78691

UR - http://www.scopus.com/inward/record.url?scp=85159074804&partnerID=8YFLogxK

U2 - 10.4018/978-1-6684-5652-1.ch001

DO - 10.4018/978-1-6684-5652-1.ch001

M3 - Chapter

SN - 9781668456521

SP - 1

EP - 47

BT - Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson’s, and Other Neurodegenerative Diseases

A2 - Zeine, Rana R.

A2 - Teasdale, Brian W.

PB - IGI Global

CY - U.S.

ER -

Steiner-Lim GZ , Coles M, Jaye K, Metri NJ, Butt AS, Christofides K et al. Medicinal cannabis for Alzheimer's disease. In Zeine RR, Teasdale BW, editors, Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson’s, and Other Neurodegenerative Diseases. U.S.: IGI Global. 2023. p. 1-47 doi: 10.4018/978-1-6684-5652-1.ch001

Medicinal cannabis for Alzheimer's disease

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this